Tags

Type your tag names separated by a space and hit enter

Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus.
J Virol. 1997 Mar; 71(3):1766-75.JV

Abstract

Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1) is required in trans to support replication of the EBV genome once per cell cycle via the latent origin of replication, oriP. EBNA-1 can also activate transcription on binding to the family of repeats of oriP to enhance some heterologous as well as native EBV promoters. We have made and screened derivatives of EBNA-1 for the ability to act as inhibitors of wild-type EBNA-1. These derivatives lack the linking or the retention functions of EBNA-1 and were analyzed for the residual ability to activate transcription and replication. We have identified derivatives of EBNA-1 that can inhibit up to 98% of wild-type EBNA-1's activities. We have also identified one derivative of EBNA-1 with only two of EBNA-1's three linking domains which can support transcription and replication inefficiently.

Authors+Show Affiliations

McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison 53706, USA.No affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

9032305

Citation

Kirchmaier, A L., and B Sugden. "Dominant-negative Inhibitors of EBNA-1 of Epstein-Barr Virus." Journal of Virology, vol. 71, no. 3, 1997, pp. 1766-75.
Kirchmaier AL, Sugden B. Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus. J Virol. 1997;71(3):1766-75.
Kirchmaier, A. L., & Sugden, B. (1997). Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus. Journal of Virology, 71(3), 1766-75.
Kirchmaier AL, Sugden B. Dominant-negative Inhibitors of EBNA-1 of Epstein-Barr Virus. J Virol. 1997;71(3):1766-75. PubMed PMID: 9032305.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus. AU - Kirchmaier,A L, AU - Sugden,B, PY - 1997/3/1/pubmed PY - 1997/3/1/medline PY - 1997/3/1/entrez SP - 1766 EP - 75 JF - Journal of virology JO - J Virol VL - 71 IS - 3 N2 - Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1) is required in trans to support replication of the EBV genome once per cell cycle via the latent origin of replication, oriP. EBNA-1 can also activate transcription on binding to the family of repeats of oriP to enhance some heterologous as well as native EBV promoters. We have made and screened derivatives of EBNA-1 for the ability to act as inhibitors of wild-type EBNA-1. These derivatives lack the linking or the retention functions of EBNA-1 and were analyzed for the residual ability to activate transcription and replication. We have identified derivatives of EBNA-1 that can inhibit up to 98% of wild-type EBNA-1's activities. We have also identified one derivative of EBNA-1 with only two of EBNA-1's three linking domains which can support transcription and replication inefficiently. SN - 0022-538X UR - https://www.unboundmedicine.com/medline/citation/9032305/Dominant_negative_inhibitors_of_EBNA_1_of_Epstein_Barr_virus_ L2 - http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=9032305 DB - PRIME DP - Unbound Medicine ER -